AnnaLee Policicchio1, Joey Mercier1, Antonia Digklia2, Ioannis A Voutsadakis3,4. 1. Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, ON, Canada. 2. University Hospital of Lausanne (CHUV), Lausanne, Switzerland. 3. Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, ON, Canada. ivoutsadakis@yahoo.com. 4. Algoma District Cancer Program, Sault Area Hospital, 750 Great Northern Road, Sault Ste. Marie, ON, P6B0A8, Canada. ivoutsadakis@yahoo.com.
Abstract
AIMS: To investigate pretreatment platelet and neutrophil counts as well as a combined platelet-neutrophil (PN) index for prognostic information in patients with rectal adenocarcinoma that received neoadjuvant treatment. PATIENTS AND METHODS: Charts from 164 patients with localized rectal adenocarcinoma were retrospectively reviewed, and 112 patients with complete data were included in the study. Patients were stratified in groups according to their neutrophil counts, platelet counts, and a combined platelet/neutrophil (PN) index. Baseline parameters of the groups were compared using the x2 test. Pathologic responses on the surgical specimen of patients with lower platelet counts (≤ 350 × 109/L), lower neutrophil counts (≤ 7.5 × 109/L), and a lower PN index were compared with those of patients with higher platelet counts (> 350 × 109/L), higher neutrophil counts (> 7.5 × 109/L), and a higher PN index using the x2 test. Kaplan-Meier curves of overall and progression free survival were constructed and compared with the log-rank test. RESULTS: A total of 33 (29.5%) patients belonged to the high-PN index group, and 79 (70.9%) patients belonged to the low-PN index group. A significant difference was present between the two groups with regard to pathologic response. Patients with both high platelet and high neutrophil counts were less likely to have a complete pathologic response than those in the low-PN index group (P = 0.039). Additionally, tumor location and tumor stage were significantly associated with complete pathologic response to neoadjuvant treatment. Patients with a complete response were more likely to present with a low tumor (≤ 5 cm from the anal verge). Likewise, patients diagnosed with stage II disease were more likely to experience complete response than those diagnosed with stage III (x2 test P = 0.016). There was no significant difference in overall and progression free survival between the two platelet groups (log-rank P = 0.73 and 0.40, respectively) and the two PN index groups (log-rank P = 0.92 and 0.43, respectively). CONCLUSION: In this retrospective analysis, the combination of higher platelet and neutrophil counts at the time of diagnosis had predictive value with respect to complete pathologic response to neoadjuvant treatment in locally advanced rectal cancer.
AIMS: To investigate pretreatment platelet and neutrophil counts as well as a combined platelet-neutrophil (PN) index for prognostic information in patients with rectal adenocarcinoma that received neoadjuvant treatment. PATIENTS AND METHODS: Charts from 164 patients with localized rectal adenocarcinoma were retrospectively reviewed, and 112 patients with complete data were included in the study. Patients were stratified in groups according to their neutrophil counts, platelet counts, and a combined platelet/neutrophil (PN) index. Baseline parameters of the groups were compared using the x2 test. Pathologic responses on the surgical specimen of patients with lower platelet counts (≤ 350 × 109/L), lower neutrophil counts (≤ 7.5 × 109/L), and a lower PN index were compared with those of patients with higher platelet counts (> 350 × 109/L), higher neutrophil counts (> 7.5 × 109/L), and a higher PN index using the x2 test. Kaplan-Meier curves of overall and progression free survival were constructed and compared with the log-rank test. RESULTS: A total of 33 (29.5%) patients belonged to the high-PN index group, and 79 (70.9%) patients belonged to the low-PN index group. A significant difference was present between the two groups with regard to pathologic response. Patients with both high platelet and high neutrophil counts were less likely to have a complete pathologic response than those in the low-PN index group (P = 0.039). Additionally, tumor location and tumor stage were significantly associated with complete pathologic response to neoadjuvant treatment. Patients with a complete response were more likely to present with a low tumor (≤ 5 cm from the anal verge). Likewise, patients diagnosed with stage II disease were more likely to experience complete response than those diagnosed with stage III (x2 test P = 0.016). There was no significant difference in overall and progression free survival between the two platelet groups (log-rank P = 0.73 and 0.40, respectively) and the two PN index groups (log-rank P = 0.92 and 0.43, respectively). CONCLUSION: In this retrospective analysis, the combination of higher platelet and neutrophil counts at the time of diagnosis had predictive value with respect to complete pathologic response to neoadjuvant treatment in locally advanced rectal cancer.
Authors: Vinatha Sreeramkumar; José M Adrover; Ivan Ballesteros; Maria Isabel Cuartero; Jan Rossaint; Izaskun Bilbao; Maria Nácher; Christophe Pitaval; Irena Radovanovic; Yoshinori Fukui; Rodger P McEver; Marie-Dominique Filippi; Ignacio Lizasoain; Jesús Ruiz-Cabello; Alexander Zarbock; María A Moro; Andrés Hidalgo Journal: Science Date: 2014-12-04 Impact factor: 47.728
Authors: Jae Hyun Kim; Jun Yeop Lee; Hae Koo Kim; Jin Wook Lee; Sung Gyu Jung; Kyoungwon Jung; Sung Eun Kim; Won Moon; Moo In Park; Seun Ja Park Journal: World J Gastroenterol Date: 2017-01-21 Impact factor: 5.742
Authors: Sivan Berger-Achituv; Volker Brinkmann; Ulrike Abu Abed; Lars I Kühn; Jonathan Ben-Ezra; Ronit Elhasid; Arturo Zychlinsky Journal: Front Immunol Date: 2013-03-06 Impact factor: 7.561